Patents by Inventor Nigel Osborn

Nigel Osborn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of aniline in the radiostabilization of oxime ligation
    Patent number: 9567372
    Abstract: A method of radiostabilizing an oxime ligation or imine formation reaction using aniline is described.
    Type: Grant
    Filed: December 15, 2011
    Date of Patent: February 14, 2017
    Assignee: GE Healthcare Limited
    Inventors: Torgrim Engell, Nigel Osborn
  • USE OF ANILINE IN THE RADIOSTABILIZATION OF OXIME LIGATION
    Publication number: 20130274436
    Abstract: A method of radiostabilizing an oxime ligation or imine formation reaction using aniline is described.
    Type: Application
    Filed: December 15, 2011
    Publication date: October 17, 2013
    Applicant: GE Healthcare Limited
    Inventors: Torgrim Engell, Nigel Osborn
  • Method of deprotection
    Patent number: 7714115
    Abstract: The invention provides a method for the synthesis of an 18F-labelled product comprising deprotected of a protected 18F-labelled compound using a deprotection agent comprising a weak acid and wherein neutralisation and buffering of the deprotected product are carried out by the addition of a neutralisation agent. The deprotected product is buffered in a pH range suitable for subsequent autoclaving and formulation into an injectable radiopharmaceutical.
    Type: Grant
    Filed: September 23, 2005
    Date of Patent: May 11, 2010
    Assignee: GE Healthcare Limited
    Inventors: Julian Grigg, Nigel Osborn
  • Method of Deprotection
    Publication number: 20080076914
    Abstract: The invention provides a method for the synthesis of an 18F-labelled product comprising deprotected of a protected 18F-labelled compound using a deprotection agent comprising a weak acid and wherein neutralisation and buffering of the deprotected product are carried out by the addition of a neutralisation agent. The deprotected product is buffered in a pH range suitable for subsequent autoclaving and formulation into an injectable radiopharmaceutical.
    Type: Application
    Filed: September 23, 2005
    Publication date: March 27, 2008
    Inventors: Julian Grigg, Nigel Osborn